News
At Plectonic Biotech, we are committed to pioneering the next generation of DNA-based immunotherapies. Follow our journey as we advance our LOGIBODY platform, secure key partnerships, and move closer to clinical application.
2024 - Expansion of Preclinical Studies
Plectonic Biotech advances its two lead indications through extensive in vivo validation and refines the LOGIBODY platform.
2023 – Plectonic Biotech at Key Industry Events
Our CEO Klaus Wagenbauer is presenting the latest findings and development strategy at PEGS-Europe conferences in Lissabon.
2023 – LOGIBODY Research Published in Nature Nanotechnology
Groundbreaking findings confirm the potential of LOGIBODY technology, demonstrating precise immune activation with reduced side effects.
2023 - Plectonic Biotech Secures SPRIND Funding
The company receives substantial funding from SPRIND to accelerate LOGIBODY preclinical development and establish scalable manufacturing.